$21.62
0.87% yesterday
Nasdaq, Jul 14, 10:00 pm CET
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Catalyst Pharmaceuticals, Inc. Stock price

$21.62
-2.05 8.66% 1M
-0.57 2.57% 6M
+0.75 3.59% YTD
+4.87 29.07% 1Y
+13.19 156.47% 3Y
+16.66 335.89% 5Y
+16.46 318.99% 10Y
+15.52 254.43% 20Y
Nasdaq, Closing price Mon, Jul 14 2025
-0.19 0.87%
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Key metrics

Basic
Market capitalization
$2.7b
Enterprise Value
$2.1b
Net debt
positive
Cash
$580.7m
Shares outstanding
122.0m
Valuation (TTM | estimate)
P/E
13.9 | 14.7
P/S
5.0 | 4.6
EV/Sales
3.9 | 3.6
EV/FCF
7.8
P/B
3.4
Financial Health
Equity Ratio
85.5%
Return on Equity
22.5%
ROCE
29.0%
ROIC
58.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$534.7m | $572.2m
EBITDA
$268.7m | $223.7m
EBIT
$231.4m | $228.7m
Net Income
$197.4m | $181.6m
Free Cash Flow
$267.6m
Growth (TTM | estimate)
Revenue
30.0% | 16.4%
EBITDA
136.3% | -3.8%
EBIT
195.4% | 17.2%
Net Income
203.1% | 10.8%
Free Cash Flow
64.1%
Margin (TTM | estimate)
Gross
86.1%
EBITDA
50.3% | 39.1%
EBIT
43.3%
Net
36.9% | 31.7%
Free Cash Flow
50.1%
More
EPS
$1.6
FCF per Share
$2.2
Short interest
8.1%
Employees
181
Rev per Employee
$2.7m
Show more

Is Catalyst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Catalyst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Catalyst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
535 535
30% 30%
100%
- Direct Costs 74 74
36% 36%
14%
460 460
29% 29%
86%
- Selling and Administrative Expenses 178 178
18% 18%
33%
- Research and Development Expense 14 14
85% 85%
3%
269 269
136% 136%
50%
- Depreciation and Amortization 37 37
6% 6%
7%
EBIT (Operating Income) EBIT 231 231
195% 195%
43%
Net Profit 197 197
203% 203%
37%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Pharmaceuticals, Inc. Stock News

Positive
FXEmpire
about one month ago
Catalyst Pharmaceuticals, Inc. (CPRX), keeps growing, bringing in Big Money.
Neutral
GlobeNewsWire
about one month ago
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career
Positive
Seeking Alpha
about one month ago
FIRDAPSE continues to drive strong performance, with Q1 2025 revenue and EPS both beating analyst expectations significantly. Catalyst reaffirmed its 2025 FIRDAPSE revenue guidance of $355–$360 million, projecting 15–20% annual growth going forward. The company has penetrated about 25% of the $1.2 billion LEMS market, with further upside as cancer-associated LEMS remains underdiagnosed.
More Catalyst Pharmaceuticals, Inc. News

Company Profile

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Head office United States
CEO Richard Daly
Employees 181
Founded 2002
Website catalystpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today